Zeptix Labs score history

Score over time

Every entry newest first

1. November 3, 2026Lowered from8.19→to8.17(-0.02)

   Market medians updated on 3 November 2026 after the Zeptix Labs tirzepatide buy-one-get-one offer ended: pricing 8.9 to 8.8.

2. October 31, 2026Raised from8.17→to8.19(+0.02)

   Pricing recomputed on 31 October 2026 under rule E1 (standing offers): the MOTS-c 10mg buy-one-get-one offer, live since 1 October 2026 and re-checked on 31 October, passed 30 days standing and now counts at $29.99 a vial. Pricing 8.8 to 8.9.

3. October 27, 2026Lowered from8.19→to8.17(-0.02)

   Market medians updated after S1Research was added pricing 8.9 to 8.8.

4. October 27, 2026Raised from8.17→to8.19(+0.02)

   Pricing recomputed on 27 October 2026: listings added for a newly reviewed vendor (Peptide Pro) moved the market median for the same products pricing 8.8 to 8.9.

5. October 24, 2026Raised from8.16→to8.17(+0.01)

   Pricing recomputed on 24 October 2026: listings added for newly reviewed vendors moved the market median for the same products: pricing 8.7 to 8.8.

6. October 23, 2026Lowered from8.17→to8.16(-0.01)

   Prices re-checked on 23 October 2026 under rule E (standing prices only): prices taken from a time-limited sale were replaced with the vendor's standing price, current prices were re-read, and other vendors' price changes moved the market medians pricing 8.8 to 8.7.

7. October 23, 2026Raised from7.89→to8.17(+0.28)

   Pricing recomputed on 23 October 2026 under the revised rule E1 (standing offers). Zeptix Labs' buy-one-get-one-free offer needs no code, has no end date and has been live since early September 2026, and a single vial costs the same as the pair, so the lowest total a buyer can pay for 8 sizes buys two vials and their price per mg counts both. Two more sizes on the offer count once they have been live 30 days. pricing 6.9 to 8.8.

8. October 23, 2026Lowered from7.90→to7.89(-0.01)

   Pricing recomputed on 23 October 2026 from current listings with the published rule (section E), after listings added or updated since 22 October, including a newly reviewed vendor's, moved the market median for the same products: pricing 7.0 to 6.9.

9. October 23, 2026Raised from7.00→to7.90(+0.90)

   Policies re-read on 23 October 2026 after the vendor reported changes, and confirmed on the live site that day: unopened returns within 30 days of delivery are refunded, lost and damaged parcels are reshipped free, and payment is by debit or credit card at checkout. shipping and refunds 5.5 to 10.0.

10. October 23, 2026Raised from6.18→to7.00(+0.82)

    Certificate library re-read on 23 October 2026 at the vendor's request: 24 certificates were confirmed at the issuing laboratories. New certificates now cover ipamorelin, MT-2, the BPC-157 and TB-500 blend, and four newly listed products, and add endotoxin and sterility screens for BPC-157 and tirzepatide. Six of the new certificates are analyses first issued to another vendor, recorded under the published supplier adjustment. Lab 6.7 to 8.2.

11. October 22, 2026Raised from6.01→to6.18(+0.17)

    Lab score recalculated on 22 October 2026 under the published core-product rule (A1b): a missing certificate on one of the 15 most widely carried products still counts fully, while on any other product it now counts at half weight, so a broad catalogue is not penalised as much for its breadth. Lab 6.4 to 6.7.

12. October 22, 2026Lowered from6.85→to6.01(-0.84)

    Re-scored on 22 October 2026 under our published rubric for shipping, pricing, operating history and transparency, applied to every vendor the same day: prices re-read from the vendor's site and matched by milligrams per vial, operating history from the earliest dated evidence of the business, and policies scored item by item. shipping and refunds 8.5 to 5.5, pricing 8.0 to 7.0, operating history 2.0 to 1.3, transparency 6.5 to 5.5.

13. October 22, 2026Raised from6.74→to6.85(+0.11)

    Lab score recalculated on 22 October 2026 under the uniform published rubric applied to every vendor: every listed product was rescored on the same fixed certificate points, with fixed deductions for site statements about testing that the certificates do not bear out. Lab 6.2 to 6.4.

14. October 20, 2026Lowered from7.89→to6.74(-1.15)

    Lab evidence re-checked on 20 October 2026 under our coverage rule, which counts a listed product with no published certificate as zero in the lab average. Certificates cover 11 of the 14 products we list that the vendor offers for sale. Lab 8.3 to 6.2.

15. October 8, 2026Raised from7.73→to7.89(+0.16)

    Four certificates dated 2026-10-07 verified first-hand at Freedom Diagnostics for GLP-3 R 10mg and 30mg, Tesamorelin 10mg and MOTS-c 10mg, each adding heavy metals by ICP-MS and a fentanyl screen. MOTS-c and Tesamorelin also moved from Accumark to Freedom Diagnostics. The vendor describes these as nine analyses; seven are present, with sterility, conformity and pH absent.